Global Downstream Processing Market Overview
Downstream Processing Market Size was valued at USD 21.5 billion in 2022 and is projected to grow from USD 24.95 Billion in 2023 to USD 82.33 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 16.1% during the forecast period (2023 - 2032). Expanding medical research investment and the biopharmaceutical industry, More CMOs are entering the downstream processing sector. Growing usage of single-use technologies in the bioprocessing industry. These are just a few of the market drivers that are driving the market.
Source: Secondary and Primary Research, MRFR Database and Analyst Review
Increased pharmaceutical R&D investment has led to greater demand for downstream processing in the biopharmaceutical industry, and this trend is expected to continue over the forecast period on the strength of a variety of business strategies and advanced technological developments.
The dominance of chromatographic separations and membrane filtrations in downstream processing, together with their high efficiency and low cost, are driving market growth. Further fueling market growth is the rising popularity of using filters to quantify viral inactivation.
The rising demand for biopharmaceuticals and the rising investment in R&D by biopharmaceutical businesses are both important contributors to the expansion of the downstream processing sector. Key factors projected to drive expansion in the downstream processing market include the rising popularity of membrane filtration for sterilizing and the significance of concentration procedures in the manufacture of biopharmaceuticals and vaccines. The downstream processing market is growing because of rising demand for innovative solutions, process optimization, and cost reduction, and a rise in the usage of techniques like centrifuge for removing biological particles from suspension.
Another piece of information claims that new mAb protocols are developed using filters that are effective against parvovirus. It is expected that the requirement for downstream processing, driven by the rising usage of viral filters in the production of antibodies and related biotherapeutics, would increase, hence driving market CAGR.
August 2023:The RevIT adeno-associated virus (AAV) Enhancer, developed by Mirus Bio, is said to enhance AAV titers by a factor of 2–4. The company claims that their technology is compatible with a wide variety of serotypes in terms of growth medium, cell lines, and transfection reagents. According to Mirus, the enhancer may double the amount of doses produced in a single run of a bioreactor while also reducing production expenses. In addition, the company asserts that the enhancer may multiply AAV titers in suspension 293 cells by a factor of 2 to 4. The enhancer may also be used in conjunction with VirusGEN, the company's transfection platform, or with the polymer-only transfection reagents that it sells. All AAV serotypes evaluated by Mirus saw an increase in titers after being treated with the RevIT Enhancer.
Downstream Processing Market Trends
- Global demand for biotechnology is growing, and biopharmaceutical companies are spending more money on research and development will boost the market growth
Due to increased pharmaceutical spending on R&D, the utilization of downstream processing in the biopharmaceutical sector is expanding, and diverse business strategies, and sophisticated technology, will drive market expansion throughout the projection period. Pharmaceutical companies worldwide spent nearly USD 200 billion on research & development in 2020, up to USD 83 million in 2019. This was highlighted in 2021. About data provided by the Congressional Budget Office. The market is growing due to downstream processing's advantages, including its high efficiency, decreased cost, and widespread domination of chromatographic separations and membrane filtrations. Additionally, the increasing use of filters in determining viral inactivation is anticipated to promote market expansion. For instance, it has been observed that the final two steps of downstream processing for antibodies frequently involve the two fundamental biopharmaceutical production technologies of virus filtration and ultrafiltration, according to an article published in May 2020 with the title "Approaches to Purification, Analysis, and Characterization of Antibody-Based Therapeutics." Additionally, virus filters have evolved to better satisfy the demands of the biopharmaceutical sector thanks to recent advances like continuous processing and higher monoclonal antibody (mAb) concentrations. Additionally, according to the same source, parvovirus-retentive filters are used to create fresh mAb procedures. Due to the growing use of viral filters in the manufacturing of antibodies and associated biotherapeutics, as well as new developments in the use of filters, it is projected that there will be a rise in the need for downstream processing, which will, in turn, spur market CAGR.
Figure 1: Total investment in research and development by country (in USD dollars)
Source: Secondary and Primary Research, MRFR Database and Analyst Review
In April 2022, Bayer said it was contemplating a partnership in which Ginkgo Bioworks would buy the West Sacramento Biologics R&D facility of Bayer and the company's internal platform for lead optimization and discovery. By signing the agreement, Bayer will be able to maintain its position as the go-to partner for biologics research, development, and business, as well as strengthen its position as the market leader in biologicals and get access to vital synthetic biology-supporting technologies. Thermo Fisher Scientific reported in January 2021 that it had funded 250 projects for COVID-19 treatment and vaccine manufacture in 2020.
Downstream Processing Market Segment Insights
Downstream Processing Technique Insights
Based on Technique, the Downstream Processing Market segmentation includes Cell Disruption, Solid-Liquid Separation, Clarification/Concentration, Purification Techniques, and Formulation. The Purification Techniques segment held the majority share in 2022 in the Downstream Processing Market data. Because there is such a strong demand for pure biopharmaceutical goods to satisfy regulatory requirements, downstream purification is crucial to improving the quality and purity of products.
Downstream Processing Product Insights
Based on product, the Downstream Processing Market segmentation includes Chromatography Columns & Resins, Filters, Membrane Adsorbers, and others. The Chromatography Columns & Resins segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Ongoing R&D initiatives to improve the efficiency and speed of chromatography systems are anticipated to boost category growth. Thermo Fisher Scientific released the HyPeak chromatography system in April 2021; it is the only single-use chromatography system for bioprocessing that the company offers and is essential to producing therapeutic proteins and vaccines. Increased chromatography system deals and innovations further aid the industry's growth.
For instance, Nova sep's chromatography equipment company was bought by Sartorius Stedim Biotech, which was announced in January 2021. Downstream Processing Application Insights
Downstream Processing Application Insights
Based on application, the Downstream Processing Market data includes Antibiotic Production, Hormone Production, Antibodies Production, Vaccine Production, and Others. The Antibiotic Production segment dominated the Downstream Processing market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The wide range of illnesses that antibiotics treat can be blamed for this quick rise. Over 700,000 people die each year as a result of antibiotic-resistant germs. As a result, there is a significant demand for antibiotic development, propelling the market growth. The surge in demand for monoclonal antibodies was the primary factor driving the fastest growth in antibody manufacturing. The introduction of cutting-edge solutions for effective antibody purification further fuels market expansion. For instance, Cytiva introduced HiScreen Fibro PrismA in January 2021 to create and purify monoclonal antibodies (mAb). The product has a fiber-based Protein A platform that boosts productivity 20 times.
Figure 2: Downstream Processing Market, by Application, 2022 & 2030 (USD Billion)
Source: Secondary and Primary Research, MRFR Database and Analyst Review
Downstream Processing End-user Insights
Based on End-user, the Downstream Processing Market data includes Biopharmaceutical Manufacturers, Contract Manufacturing Organizations, Other. The Biopharmaceutical Manufacturers segment dominated the Downstream Processing market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Due to a rise in the need for biopharmaceuticals to treat various diseases throughout the world.
Downstream Processing Regional Insights
The analysis offers market insights for North America, Europe, Asia-Pacific, and the rest of the world, organized by region. The North America Downstream Processing market accounted for USD 9.84 billion in 2022 with a share of around 45.80%, and is expected to exhibit a significant CAGR growth during the study period. Because of increased healthcare spending, government backing for developing bioprocess technology, and an established infrastructure for healthcare. Additionally, the area has seen significant joint ventures with pharmaceutical behemoths that heavily fund the research and development of vaccines and biopharmaceuticals. Key market participants are also strengthening their presence in this area. For instance, Richmond, Virginia-based Thermo Fisher Scientific Inc. recently announced an investment of USD 97 million to expand its clinical research facilities there.
Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: DOWNSTREAM PROCESSING MARKET SHARE BY REGION 2022 (%)
Source: Secondary and Primary Research, MRFR Database and Analyst Review
Asia Pacific Downstream Processing market is anticipated to expand at the quickest rate between 2022 and 2030 due to a rise in biotechnology investments from both consumers and innovators. A big population base drives the need for improved medical facilities, and companies are eager to apply quick analytical techniques to enable in-process designing and bioprocessing. Due to the expanding biopharmaceutical sector and increasing demand for drugs and vaccines, China Downstream Processing market has dominated the Asia Pacific area. The India Downstream Processing market was the fastest-growing market in the region.
The Europe Downstream Processing market is driven by expanding R&D spending by biopharmaceutical firms, rising R&D investment, and market participants that substantially contribute to market growth. For instance, ThermoFisherScientific, Inc. stated in November 2019 that it would invest almost USD 24 million in its Inchinnan, Scotland, location to increase its large-volume liquid manufacturing capacity for cell culture medium and so enhance its worldwide bioproduction capabilities. Sartorius (Germany), a top global partner in life science research and the biopharmaceutical sector, purchased several of Danaher Corporation's life science companies in April 2020. (U.S.). The acquisition will support cutting-edge reagents, biosensors, and devices for protein analysis that are employed in drug development. Moreover, the U.K. Downstream Processing market held the largest market share, and the Germany Downstream Processing market was the fastest-growing market in the region.
Downstream Processing Key Market Players & Competitive Insights
Major industry companies are investing a lot of money in R&D to expand their product offerings, which will spur further market expansion for the Downstream Processing industry. With significant industry changes, including new product launches, mergers and acquisitions, contractual agreements, higher investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their global presence. To grow and remain in a market that is becoming increasingly competitive, Downstream Processing industry competitors must provide affordable products.
Manufacturing locally to save money on operational expenses is one of the main business methods producers use in the global Downstream Processing industry to benefit customers and develop the market sector. Some of the most important advantages to medicine in recent years have come from the Downstream Processing industry. The Downstream Processing market major player such Thermo Fisher Scientific Inc. (US), Sartorius Stedim Biotech S.A. (France), Merck Millipore (Germany), Danaher Corporation (U.S.), 3M Company (U.S.), Boehringer Ingelheim (Germany), Lonza Group AG (Switzerland), Eppendorf AG (Switzerland), Corning Incorporated (U.S.), Asahi Kasei Corporation (Japan) Company.
Named after the Merck Group, which was established in Germany in 1668 and of which it was once the American arm, Merck & Co., Inc. is an American global pharmaceutical corporation with its headquarters in Rahway, New Jersey. Outside of the United States and Canada, the corporation trades as Merck Sharp & Dohme or MSD. Merck and Agilent Technologies joined forces in June 2022 to close the industry gap in process analytical technologies (PAT) for downstream processing. By the agreement, the businesses combine the bioprocess portfolio of Merck with the cutting-edge analytical technologies of Agilent Technologies to expand real-time monitoring and automated process control of critical process parameters (CPPs) and critical quality attributes (CQAs) in downstream processing (DSP).
Sartorius AG serves the Bioprocess Solutions and Lab Products & Services markets as a multinational provider of laboratory and pharmaceutical equipment. The chromatography division of Novasep, which consists of cutting-edge systems for the continuous manufacturing of biologics and chromatography systems primarily suited for smaller biomolecules like oligonucleotides, peptides, and insulin, was acquired by Sartorius Stedim Biotech in February 2022. November 2022:A&B Process Systems, which is owned by JBT, introduced cutting-edge processing equipment for farm-raised beef in November 2022. Customers have the option of adapting ReadyGo Bioreactor to their specific procedures, and the system is believed to be in line with international bio-processing standards. The technology was created to help processors in the sector deal with problems including scalability, lead time, and capital expense without increasing production prices. Successfully meeting the protein needs of a growing worldwide population was a top priority for JBT, a global leader in both upstream and downstream processing solutions for the protein industry.
Key Companies in the Downstream Processing market include
- Thermo Fisher Scientific Inc. (U.S.)
- Sartorius Stedim Biotech S.A. (France)
- Merck Millipore (Germany)
- Danaher Corporation (U.S.)
- 3M Company (U.S.)
- Boehringer Ingelheim (Germany)
- Lonza Group AG (Switzerland)
- Eppendorf AG (Switzerland)
- Corning Incorporated (U.S.)
- Asahi Kasei Corporation (Japan)
Downstream Processing Industry Developments
- July 2021:To lower production costs and improve the feasibility of gene therapies as therapy alternatives for patients, ThermoFisherScientific, Inc. (U.S.) introduced a set of technologies to enable Adeno-associated Viral (AAV) manufacture. This contained enhanced purification resins, a media panel, and a gene kit.
- March 2020:The Life Sciences division of General Electric Company (U.S.) sold its Biopharma business to Danaher Corporation (U.S.), which was renamed Cytiva.
- April 2020:Sartorius AG (France) agreed to acquire parts of Danaher's Life Science portfolio, which complemented Sartorius' laboratory and bioprocess business portfolio.
Downstream Processing Market Segmentation
Downstream Processing Technique Outlook (USD billion, 2018-2030)
- Cell Disruption
- Solid-Liquid Separation
- Clarification/Concentration
- Purification Techniques
- Formulation
Downstream Processing Product Outlook (USD billion, 2018-2030)
Downstream Processing Application Outlook (USD billion, 2018-2030)
- Antibiotic Production
- Hormone Production
- Antibodies Production
- Vaccine Production
- Other
Downstream Processing End-User Outlook (USD billion, 2018-2030)
- Biopharmaceutical Manufacturers
- Contract Manufacturing Organization
- Other
Downstream Processing Regional Outlook (USD Billion, 2018-2030)
-
North America
-
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
-
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
-
Rest of the World
- Middle East
- Africa
- Latin America
| Report Attribute/Metric |
Details |
| Market Size 2022 |
USD 21.5 billion |
| Market Size 2023 |
USD 24.95 billion |
| Market Size 2030 |
USD 82.33 billion |
| Compound Annual Growth Rate (CAGR) |
 16.1% (2023-2032) |
| Base Year |
2022 |
| Market Forecast Period |
2023-2032 |
| Historical Data |
2018 - 2021 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Variety, Form, Distribution Channel and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The U.S, Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Thermo Fisher Scientific Inc. (U.S.),   Sartorius Stedim Biotech S.A. (France),  Merck Millipore (Germany),  Danaher Corporation (U.S.), 3M Company (U.S.),  Boehringer Ingelheim (Germany), Lonza Group AG (Switzerland), Eppendorf AG (Switzerland), Corning Incorporated (U.S.), Asahi Kasei Corporation (Japan)Company |
| Key Market Opportunities |
Advances in downstream processing Increasing demand for monoclonal antibodies |
| Key Market Dynamics |
Growing biopharmaceutical industry and increasing spending on medical research An increasing number of CMOs in the market for downstream processing Increasing adoption of single-use technology in bioprocessing |
Downstream Processing Market Highlights:
Frequently Asked Questions (FAQ) :
The Downstream Processing Market size was valued at USD 21.5 Billion in 2022.
The global market is projected to grow at a CAGR of 16.1% from 2023-2032.
North America had the largest share in the Downstream Processing Market.
The key players in the market are Thermo Fisher Scientific Inc. (U.S.), Sartorius Stedim Biotech S.A. (France), Merck Millipore (Germany), Danaher Corporation (U.S.), 3M Company (U.S.), Boehringer Ingelheim (Germany), Lonza Group AG (Switzerland), Eppendorf AG (Switzerland), Corning Incorporated (U.S.), Asahi Kasei Corporation (Japan)Company.
The purification technique category dominated the market in 2022.
Biopharmaceutical had the largest share in the Downstream Processing Market.
